Trading Ideas

* Easy Allied Health (or “Easy Allied”) is comprised of a network of health experts focused on the fields of Physiotherapy, Occupational Therapy, Kinesiology, and Clinical Counselling. Easy Allied’s mission is to provide a team of integrated health professionals to support the community in the most convenient way for clients to regain and maintain independence and manage pain. …read more […]

…read more […]

The Luminar Technologies IPO has investors waiting in anticipation. The company operated in stealth until 2017 when it revealed its product. It provides advanced technology for autonomous driving vehicles. And investors want to invest in the future.
But is Luminar Technologies stock a good investment opportunity? Here’s what we know…
Luminar Technologies IPO: The Business

CEO Austin Russel founded Luminar Technologies in 2012. Russel was a Thiel fellow, meaning he received $100,000 over a two-year period to drop out of Standford University and pursue his idea. Luminar is a global leader in lidar autonomous driving technology. Lidar is the use of lasers to …read more […]

The latest analyst coverage could presage a bad day for Novavax, Inc. (NASDAQ:NVAX), with the analysts making… …read more […]

Investors in Las Vegas Sands Corp. (NYSE:LVS) had a good week, as its shares rose 9.8% to close at US$49.81 following… …read more […]

Lockheed Martin Corporation (NYSE:LMT) shareholders are probably feeling a little disappointed, since its shares fell… …read more […]

iRobot Corporation (NASDAQ:IRBT) investors will be delighted, with the company turning in some strong numbers with its… …read more […]

MONTREAL and CHARLOTTE, N., Oct. …read more […]

Edwards Lifesciences Corporation (NYSE:EW) just released its quarterly report and things are looking bullish. The… …read more […]

I consider myself to be an expert of sorts on retirement. Not because I’ve studied the subject, but because I’ve retired three times.
Yes, I’m a three-time failure at retiring. But I’ve learned from my mistakes. Today, I’d like to tell you about the worst mistake retirees make.
It’s a common mistake… yet I’ve never heard it mentioned by retirement experts. Nor have I read a word about it in retirement books…
The biggest mistake retired people make is giving up all their active income.
When I say active income, I mean the money you make through your labor or through a business you …read more […]

The U.S. health regulator’s approval on Thursday for its use in hospitalized patients came despite the World Health Organization last week saying the drug did not have a substantial effect on patients’ length of hospital stay or chances of survival in a global trial. The U.S. Food and Drug Administration’s (FDA) backing signals its confidence in Gilead’s U.S.-based study results, which showed the drug was able to cut time to recovery in patients, Piper Sandler analyst Tyler Van Buren said in a client note. Remdesivir has been available under an FDA emergency use authorization since May, after a …read more […]

Adobe Inc. (NASDAQ:ADBE) saw a double-digit share price rise of over 10% in the past couple of months on the NASDAQGS… …read more […]

Align Technology, Inc. (NASDAQ:ALGN) led the NASDAQGS gainers with a relatively large price hike in the past couple of… …read more […]

(Bloomberg) — T. Rowe Price Group Inc., UBS Asset Management and FMR LLC, the parent of Fidelity Investments, are among the money managers angling for a piece of Ant Group Co.’s blockbuster initial public offering, a person familiar with the matter said.Each of the firms is considering investments worth several billion dollars in Ant’s Hong Kong-listed shares, though they’ve yet to finalize plans and there’s no guarantee they’ll get an allocation, the person said, asking not to be identified discussing private information.Ant is expected to start taking orders for the Hong Kong portion of its dual listing on Oct. 26 …read more […]

(Bloomberg) — The U.S. Food and Drug Administration approved Gilead Sciences Inc.’s antiviral therapy remdesivir on Thursday, making it the first drug to obtain formal clearance for treating the coronavirus.Regulators had granted an emergency-use authorization for remdesivir earlier this year, and since then the drug has become a widely used therapy in hospitalized Covid-19 patients. It was given to President Donald Trump this month when he was diagnosed with the virus.The approval of remdesivir, sold under the brand name Veklury, will allow Gilead to market the drug and talk about its benefits to doctors, nurses, and patients. That could help …read more […]